International Ophthalmology

, Volume 38, Issue 5, pp 2021–2030 | Cite as

Effect of diquafosol tetrasodium 3% on the conjunctival surface and clinical findings after cataract surgery in patients with dry eye

  • Lian Cui
  • Ying Li
  • Hyo Seok Lee
  • Jee Myung Yang
  • Won Choi
  • Kyung Chul YoonEmail author
Original Paper



To investigate the effects of diquafosol tetrasodium (DT) 3% on conjunctival impression cytologic findings in addition to clinical symptoms and signs after cataract surgery in patients with preexisting dry eye disease (DED).


Ninety-four eyes of 94 patients with DED who underwent uneventful cataract surgery were included. In total, 50 patients were treated with DT 3% (group A), while 44 patients were treated with sodium hyaluronate 0.1% (group B) postoperatively, along with topical antibiotics and steroids. Conjunctival impression cytology was performed at baseline and at 4 and 12 weeks after surgery. Visual acuity, ocular surface disease index (OSDI), tear film breakup time (TBUT), keratoepitheliopathy score, Schirmer’s test, and tear clearance rate were measured at baseline and at 1, 4, and 12 weeks, and corneal aberration was analyzed at baseline and at 4 and 12 weeks.


The grade of conjunctival squamous metaplasia was lower at 12 weeks, and goblet cell density was higher at 4 and 12 weeks in group A than in group B (P < 0.05). Compared with group B, group A showed significantly lower OSDI scores at 4 and 12 weeks, longer TBUT at 1, 4, and 12 weeks, lower keratoepitheliopathy scores at 1 and 12 weeks, and lower total root-mean-square score and spherical aberrations at 4 weeks after surgery (P < 0.05).


DT 3% eye drops application after cataract surgery was effective in improving conjunctival epithelial morphology and goblet cell density as well as clinical findings in patients with DED.


Diquafosol Impression cytology Cataract surgery Dry eye 



This study was partially supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2017R1A2B4003367) and the Chonnam National University Hospital Biomedical Research Institute (CRI 13906-22 and CRI16020-1).

Compliance with ethical standards

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.


  1. 1.
    McCarty CA, Bansal AK, Livingston PM, Stanislasky YL, Taylor HR (1998) The epidemiology of dry eye in Melbourne, Australia. Ophthalmology 105(6):1114–1119CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Apostol S, Filip M, Dragne C, Filip A (2003) Dry eye syndrome: etiological and therapeutic aspects. Oftalmologia 59(4):28–31PubMedPubMedCentralGoogle Scholar
  3. 3.
    Lin PY, Tsai SY, Cheng CY, Liu JH, Chou P, Hsu WM (2003) Prevalence of dry eye among an elderly Chinese population in Taiwan: the Shihpai eye study. Ophthalmology 110(6):1096–1101CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Listed NA (2007) The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop. Ocul Surf 5(2):75–92Google Scholar
  5. 5.
    Colorado LH, Alzahrani Y, Pritchard N, Efron N (2016) Time course of changes in goblet cell density in symptomatic and asymptomatic contact lens wearers. Invest Ophthalmol Vis Sci 57(6):2560–2566CrossRefGoogle Scholar
  6. 6.
    Doughty MJ (2012) Goblet cells of the normal human bulbar conjunctiva and their assessment by impression cytology sampling. Ocul Surf 10(3):149–169CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Li XM, Hu L, Hu J, Wang W (2007) Investigation of dry eye disease and analysis of the pathogenic factors in patients after cataract surgery. Cornea 26(9 Suppl 1):S16–S20CrossRefPubMedCentralGoogle Scholar
  8. 8.
    Cho YK, Kim MS (2009) Dry eye after cataract surgery and associated intraoperative risk factors. Korean J Ophthalmol 23(2):65–73CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Jee D, Park M, Lee HJ, Kim MS, Kim EC (2015) Comparison of treatment with preservative-free versus preserved sodium hyaluronate 0.1% and fluorometholone 0.1% eyedrops after cataract surgery in patients with preexisting dry-eye syndrome. J Cataract Refract Surg 41(4):756–763CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Ram J, Gupta A, Brar G, Kaushik S, Gupta A (2002) Outcomes of phacoemulsification in patients in dry eye. J Cataract Refract Surg 28(8):1386–1389CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Michael R, Wegener A (2004) Estimation of safe exposure time from an ophthalmic operating microscope with regard to ultraviolet radiation and blue-light hazards to the eye. J Opt Soc Am A Opt Image Sci Vis 21(8):1388–1392CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Stonecipher KG, Torkildsen GL III, Ousler GW, Morris S, Villanueva L, Hollander DA (2016) The impact study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye. Clin Ophthalmol 13(10):887–895CrossRefGoogle Scholar
  13. 13.
    Fujihara T, Murakami T, Fujita H, Nakamura M, Nakata K (2001) Improvement of corneal barrier function by the P2Y2 agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci 42(1):96–100PubMedPubMedCentralGoogle Scholar
  14. 14.
    Fujihara T, Murakami T, Nagano T, Nakamura M, Nakata K (2002) INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model. J Ocul Pharmacol Ther 18(4):363–370CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Lau OC, Samarawickrama C, Skalicky SE (2014) P2Y2 receptor agonists for the treatment of dry eye disease: a review. Clin Ophthalmol 30:327–334Google Scholar
  16. 16.
    Nichols KK, Yerxa B, Kellerman DJ (2004) Diquafosol tetrasodium: a novel dry eye therapy. Expert Opin Invest Drugs 13(1):47–54CrossRefGoogle Scholar
  17. 17.
    Nakamura M, Imanaka T, Sakamoto A (2012) Diquafosol ophthalmic solution for dry eye treatment. Adv Ther 29(7):579–589CrossRefPubMedCentralGoogle Scholar
  18. 18.
    Jung HH, Kang YS, Sung MS, Yoon KC (2015) Clinical efficacy of topical 3% diquafosol tetrasodium in short tear film break-up time dry eye. J Korean Ophthalmol Soc 56(3):339–344CrossRefGoogle Scholar
  19. 19.
    Shigeyasu C, Yamada M, Akune Y, Tsubota K (2015) Diquafosol sodium ophthalmic solution for the treatment of dry eye: clinical evaluation and biochemical analysis of tear composition. Jpn J Ophthalmol 59(6):415–420CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Mori Y, Nejima R, Masuda Maruyama Y, Minami K, Miyata K et al (2014) Effect of diquafosol tetrasodium eye drop for persistent dry eye after laser in situ keratomileusis. Cornea 33(7):659–662CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Bae J, Doh SH, Chung SK (2016) The effect of topical diquafosol tetrasodium 3% on dry eye after cataract surgery. Curr Eye Res 41(10):1281–1285CrossRefGoogle Scholar
  22. 22.
    Lee JH, Song IS, Kim KL, Yoon SY (2016) Effectiveness and optical quality of topical 3% diquafosl versus 0.05% cyclosporine A in dry eye patients following cataract surgery. J Ophthalmol 2016:8150757PubMedPubMedCentralGoogle Scholar
  23. 23.
    Park DH, Chung JK, Seo DR, Lee SJ (2016) Clinical effects and safety of 3% diquafosol ophthalmic solution for patients with dry eye after cataract surgery: a randomized controlled trial. Am J Ophthalmol 163:122–131CrossRefPubMedCentralGoogle Scholar
  24. 24.
    Li Y, Kuang K, Yerxa B, Wen Q, Rosskothen H, Fischbarg J (2001) Rabbit conjunctival epithelium transports fluid, and P2Y22 receptor agonists stimulate Cl and fluid secretion. Am J Physiol Cell Physiol 281(2):C595–C602CrossRefPubMedCentralGoogle Scholar
  25. 25.
    Lee HS, Ji YS, Yoon KC (2014) Efficacy of hypotonic 0.18% sodium hyaluronate eye drops in patients with dry eye disease. Cornea 33(9):946–951CrossRefPubMedCentralGoogle Scholar
  26. 26.
    Hwang HS, Sung YM, Lee WS, Kim EC (2014) Additive effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops. Cornea 33(9):935–941CrossRefPubMedCentralGoogle Scholar
  27. 27.
    Yoon KC, Heo H, Im SK, You IC, Kim YH, Park YG (2007) Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. Am J Ophthalmol 144(1):86–92CrossRefPubMedCentralGoogle Scholar
  28. 28.
    Singh R, Joseph A, Umapathy T, Tint NL, Dua HS (2005) Impression cytology of the ocular surface. Br J Ophthalmol 89(12):1655–1659CrossRefPubMedCentralGoogle Scholar
  29. 29.
    Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL (2000) Reliability and validity of the ocular surface disease index. Arch Ophthalmol 118(5):615–621CrossRefPubMedCentralGoogle Scholar
  30. 30.
    Yoon KC, Im SK, Kim HG, You IC (2011) Usefulness of double vital staining with 1% fluorescein and 1% lissamine green in patients with dry eye syndrome. Cornea 30(9):972–976CrossRefPubMedCentralGoogle Scholar
  31. 31.
    Yoon KC, Sk Im, Seo MS (2004) Changes of tear film and ocular surface in diabetes mellitus. Korean J Ophthalmol 18(2):168–174CrossRefPubMedCentralGoogle Scholar
  32. 32.
    Jung HH, Ji YS, Sung MS, Kim KK, Yoon KC (2015) Long-term outcome of treatment with topical corticosteroids for severe dry eye associated with Sjögren’s syndrome. Chonnam Med J 51(1):26–32CrossRefPubMedCentralGoogle Scholar
  33. 33.
    Yoon KC, Park CS, You IC, Choi HJ, Lee KH, Im SK et al (2010) Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome. Invest Ophthalmol Vis Sci 51(2):643–650CrossRefPubMedCentralGoogle Scholar
  34. 34.
    Jung HH, Ji YS, Oh HJ, Yoon KC (2014) Higher order aberrations of the corneal surface after laser subepithelial keratomileusis. Korean J Ophthalmol 28(4):285–291CrossRefPubMedCentralGoogle Scholar
  35. 35.
    Denoyer A, Rabut G, Baudouin C (2012) Tear film aberration dynamics and vision-related quality of life in patients with dry eye disease. Ophthalmology 119(9):1811–1818CrossRefPubMedCentralGoogle Scholar
  36. 36.
    Chung YW, Oh TH, Chung SK (2013) The effect of topical cyclosporine 0.05% on dry eye after cataract surgery. Korean J Ophthalmol 27(3):167–171CrossRefPubMedCentralGoogle Scholar
  37. 37.
    Kasetsuwan N, Satitpitakul V, Changul T, Jariyakosol S (2013) Incidence and pattern of dry eye after cataract surgery. PLoS ONE 8(11):e78657CrossRefPubMedCentralGoogle Scholar
  38. 38.
    Gong L, Sun X, Ma Z, Wang Q, Xu X, Chen X et al (2015) A randomized, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore. Br J Ophthalmol 99(7):903–908CrossRefPubMedCentralGoogle Scholar
  39. 39.
    Yang JM, Choi W, Kim N, Yoon KC (2015) Comparison of topical cyclosporine and diquafosol treatment in dry eye. Optom Vis Sci 92(9):e296–e302CrossRefPubMedCentralGoogle Scholar
  40. 40.
    Ishibashi K, Ckamura K, Yamazaki J (2008) Involvement of apical P2Y2 receptor-regulated CFTR activity in muscarinic stimulation of Cl(-) reabsorption in rat submandibular gland. Am J Physiol Regul Integr Comp Physiol 294(5):R1729–R1736CrossRefPubMedCentralGoogle Scholar
  41. 41.
    Miyake G, Ota I, Miyake K, Zako M, Iwaki M (2014) Effects of topical diquafosol pretreatment on intraoperative corneal wetting. J Cataract Refract Surg 40(10):1682–1688CrossRefPubMedCentralGoogle Scholar
  42. 42.
    Oh T, Jung Y, Chang D, Kim J, Kim H (2012) Changes in the tear film and ocular surface after cataract surgery. Jpn J Ophthalmol 56(2):113–118CrossRefPubMedCentralGoogle Scholar
  43. 43.
    Murakami T, Fujihara T, Horibe Y, Nakamura M (2004) Diquafosol elicits increase in net Cl transport through P2Y2 receptor stimulation in rabbit conjunctiva. Ophthalmic Res 36(2):89–93CrossRefPubMedCentralGoogle Scholar
  44. 44.
    Jin SW, Min JS (2016) Clinical evaluation of the effect of diquafosol ophthalmic solution in glaucoma patients with dry eye syndrome. Jpn J Ophthalmol 60(3):150–155CrossRefPubMedCentralGoogle Scholar
  45. 45.
    Aragona P, Micali A, Paladino G, Ferreri F, Puzzolo D (2007) Effects of tear substitutes on conjunctival epithelium of mice. Ophthalmic Res 39(5):265–275CrossRefPubMedCentralGoogle Scholar
  46. 46.
    Tauber J, Davitt WF, Bokosky JE, Nichols KK, Yerxa BR, Schaberg AE et al (2004) Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (IN365) ophthalmic solution for the treatment of dry eye. Cornea 23(8):784–792CrossRefPubMedCentralGoogle Scholar
  47. 47.
    Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K (2012) Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. Ophthalmology 119(10):1954–1960CrossRefPubMedCentralGoogle Scholar
  48. 48.
    Kaido M, Uchino M, Kojuma T, Dogru M, Tsubota K (2013) Effects of diquafosol tetrasodium administration on visual function in short break-up time dry eye. J Ocul Phamacol Ther 29(6):595–603CrossRefGoogle Scholar
  49. 49.
    Kamiya K, Nakanishi M, Ishii R, Kobashi H, Lgarashi A, Sato N et al (2012) Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study. Eye (Lond) 26(10):1363–1368CrossRefGoogle Scholar
  50. 50.
    Hwang J, Chung SH, Jeon S, Kwok SK, Park SH, Kim MS (2014) Comparison of clinical efficacies of autologous serum eye drops in patients with primary and secondary Sjögren syndrome. Cornea 33(7):663–667CrossRefPubMedCentralGoogle Scholar
  51. 51.
    Sutu C, Fukuoka H, Afshari NA (2016) Mechanisms and management of dry eye in cataract surgery patients. Curr Opin Ophthalmol 27(1):24–30CrossRefPubMedCentralGoogle Scholar
  52. 52.
    Toda I, Ide T, Fukumoto T, Ichihashi Y, Tsubota K (2014) Combination therapy with diquafosol tetrasodium and sodium hyaluronate in patients with dry eye after laser in situ keratomileusis. Am J Ophthalmol 157(3):616–622CrossRefPubMedCentralGoogle Scholar
  53. 53.
    Jones LT (1966) The lacrimal secretory system and its treatment. Am J Ophthalmol 62(1):47–60CrossRefPubMedCentralGoogle Scholar
  54. 54.
    Koh S, Maeda N, Ikeda C, Oie Y, Soma T, Tsujikawa M et al (2014) Effect of diquafosol ophthalmic solution on the optical quality of the eyes in patients with aqueous-deficient dry eye. Acta Ophthalmol 92(8):e671–e675CrossRefPubMedCentralGoogle Scholar
  55. 55.
    Liu Z, Pflugfelder SC (1999) Corneal surface regularity and the effect of artificial tears in aqueous tear deficiency. Ophthalmology 106(5):939–943CrossRefPubMedCentralGoogle Scholar
  56. 56.
    Rieger G (1992) The importance of the precorneal tear film for the quality of optical imaging. Br J Ophthalmol 76(3):157–158CrossRefPubMedCentralGoogle Scholar
  57. 57.
    McGinnigle S, Eperjesi E, Naroo SA (2014) A preliminary investigation into the effects of ocular lubricants on higher order aberrations in normal and dry eye subjects. Cont Lens Anterior Eye 37(2):106–110CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2017

Authors and Affiliations

  1. 1.Department of OphthalmologyChonnam National University Medical School and HospitalGwangjuSouth Korea
  2. 2.Department of Biomedical Sciences and Center for Creative Biomedical ScientistsChonnam National UniversityGwangjuSouth Korea
  3. 3.Graduate School of Medical Science and EngineeringKorea Advanced Institute of Science and TechnologyDaejeonSouth Korea

Personalised recommendations